Microfluidic liver-on-a-chips overcome the shortcomings of conventional 2D models such as limited cell-cell and cell-ECM interaction as well as inadequacies of animal models in predicting the drug’s performance in the human body. Moreover, liver-on-a-chips help in reducing the number of animal models that have to be sacrificed.